Assembly Biosciences, Inc. financial data

Symbol
ASMB on Nasdaq
Industry
Pharmaceutical Preparations
Location
Two Tower Place, 7 Th Floor, South San Francisco, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
VENTRUS BIOSCIENCES INC (to 7/11/2014)
Latest financial report
10-Q - Q3 2024 - Nov 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 287 % -58.2%
Debt-to-equity 251 % +1074%
Return On Equity -121 % -4.33%
Return On Assets -34.6 % +64%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 6.36M shares -90.3%
Common Stock, Shares, Outstanding 6.35M shares -87.9%
Entity Public Float 60M USD -40.3%
Common Stock, Value, Issued 6K USD -88.7%
Weighted Average Number of Shares Outstanding, Basic 6.35M shares +45%
Weighted Average Number of Shares Outstanding, Diluted 6.35M shares +45%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 52.7M USD -3.81%
General and Administrative Expense 22.1M USD +8.76%
Operating Income (Loss) -46.4M USD +38.1%
Nonoperating Income (Expense) 6.07M USD +152%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -9.61M USD +33.3%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -40.8M USD +43.8%
Earnings Per Share, Basic -6.9 USD/shares +79.2%
Earnings Per Share, Diluted -6.9 USD/shares +79.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 28.5M USD +6.74%
Accounts Receivable, after Allowance for Credit Loss, Current 0 USD
Assets, Current 98.2M USD +97.7%
Property, Plant and Equipment, Net 316K USD -43.7%
Operating Lease, Right-of-Use Asset 1.42M USD +68.4%
Other Assets, Noncurrent 312K USD -43.5%
Assets 100M USD +94.2%
Accounts Payable, Current 1.34M USD +76.1%
Employee-related Liabilities, Current 4.12M USD +10.3%
Accrued Liabilities, Current 4.77M USD +22.6%
Contract with Customer, Liability, Current 32.6M USD
Liabilities, Current 41.6M USD +484%
Contract with Customer, Liability, Noncurrent 32.5M USD +1090%
Operating Lease, Liability, Noncurrent 113K USD +126%
Liabilities 74.3M USD +649%
Accumulated Other Comprehensive Income (Loss), Net of Tax -156K USD +43.3%
Retained Earnings (Accumulated Deficit) -816M USD -5.27%
Stockholders' Equity Attributable to Parent 26M USD -37.7%
Liabilities and Equity 100M USD +94.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -18.4M USD +21.6%
Net Cash Provided by (Used in) Financing Activities 0 USD -100%
Net Cash Provided by (Used in) Investing Activities 17.3M USD +72.7%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 6.35M shares -87.9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.09M USD +87.8%
Deferred Tax Assets, Valuation Allowance 202M USD +10%
Deferred Tax Assets, Gross 203M USD +9.88%
Operating Lease, Liability 2.34M USD -32.4%
Payments to Acquire Property, Plant, and Equipment 14K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -40.7M USD +43.4%
Lessee, Operating Lease, Liability, to be Paid 2.57M USD -29.7%
Property, Plant and Equipment, Gross 595K USD -75.5%
Operating Lease, Liability, Current 1.33M USD +52.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.17M USD +1508%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.4M USD -60.6%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 232K USD +16.6%
Lessee, Operating Lease, Liability, to be Paid, Year Three 37K USD +270%
Deferred Tax Assets, Operating Loss Carryforwards 148M USD +2.74%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 4.5M USD +16.1%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 32K USD -74.2%
Deferred Tax Assets, Net of Valuation Allowance 646K USD -20.3%
Share-based Payment Arrangement, Expense 3.33M USD -46.1%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%